Who
Michael Goettler
Director
Company insider
Files Form 4 as: Director, Bausch Health Companies; Chief Executive Officer, Viatris; Group President, Pfizer.
In numbers
- Trades disclosed
- 86
- Buys
- 1
- Sells
- 1
- Bought
- $497K
- Sold
- $762K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 1 Aug 2018
- Last trade
- 22 May 2026
- Last filed
- 26 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 May 2026filed 26 May 2026 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —45,871 at $0.00 | filing |
| 22 May 2026filed 26 May 2026 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —45,871 at $0.00 | filing |
| 25 Jul 2025filed 29 Jul 2025 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —30,149 at $0.00 | filing |
| 4 Mar 2023filed 6 Mar 2023 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —104,085 at $0.00 | filing |
| 4 Mar 2023filed 6 Mar 2023 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,741.52 at $0.00 | filing |
| 4 Mar 2023filed 6 Mar 2023 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —104,085 at $0.00 | filing |
| 4 Mar 2023filed 6 Mar 2023 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $507K45,569 at $11.13 | filing |
| 4 Mar 2023filed 6 Mar 2023 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —3,742 at $0.00 | filing |
| 4 Mar 2023filed 6 Mar 2023 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $18K1,639 at $11.13 | filing |
| 2 Mar 2023filed 6 Mar 2023 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —84,908 at $0.00 | filing |
| 2 Mar 2023filed 6 Mar 2023 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,714.74 at $0.00 | filing |
| 2 Mar 2023filed 6 Mar 2023 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —84,908 at $0.00 | filing |
| 2 Mar 2023filed 6 Mar 2023 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $414K37,173 at $11.13 | filing |
| 2 Mar 2023filed 6 Mar 2023 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —6,715 at $0.00 | filing |
| 2 Mar 2023filed 6 Mar 2023 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $33K2,940 at $11.13 | filing |
| 27 Feb 2023filed 1 Mar 2023 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —119,975 at $0.00 | filing |
| 27 Feb 2023filed 1 Mar 2023 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,752.75 at $0.00 | filing |
| 27 Feb 2023filed 1 Mar 2023 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —119,975 at $0.00 | filing |
| 27 Feb 2023filed 1 Mar 2023 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code F | $588K52,526 at $11.20 | filing |
| 27 Feb 2023filed 1 Mar 2023 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —8,753 at $0.00 | filing |
News
Pfizer layoffs announced at Rocky Mount, Sanford facilities in NCPFE · abc11.com · 21 Oct 2026Critical Analysis: Nexentis Technologies (NASDAQ:NXTS) versus Pfizer (NYSE:PFE)PFE · dailypolitical.com · 19 Oct 2026Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally?PFE · fool.com · 19 Oct 2026Viatris' Dividend Has Room to Grow, but Will Management Deliver?VTRS · insidermonkey.com · 19 Oct 2026Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of PresbyopiaVTRS · prnewswire.com · 16 Oct 2026Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?VTRS · insidermonkey.com · 9 Oct 2026
0 headlines in the last 90 days name Michael Goettler; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.